Filing Details

Accession Number:
0001493152-20-022869
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-03 06:13:35
Reporting Period:
2020-11-30
Accepted Time:
2020-12-03 06:13:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1335105 Lixte Biotechnology Holdings Inc. LIXT Pharmaceutical Preparations (2834) 202903526
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1369455 F Philip Palmedo 248 Route 25A, No. 2
East Setauket, NY 11733
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-30 21,053 $4.75 32,056 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Warrants to Purchase Common Stock Acquisiton 2020-11-30 21,053 $4.75 21,053 $5.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,053 2020-11-30 2025-11-30 No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 183,333 Indirect By Philip Palmedo L.P.
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Options to Purchase Common Stock $0.72 2016-04-25 2021-04-25 75,000 75,000 Direct
Common Stock Options to Purchase Common Stock $0.90 2017-10-16 2022-10-16 8,333 8,333 Direct
Common Stock Options to Purchase Common Stock $6.60 2019-05-22 2024-05-22 8,333 8,333 Direct
Common Stock Warrants to Purchase Common Stock $6.00 2018-12-07 2022-12-07 16,667 16,667 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-04-25 75,000 75,000 Direct
2022-10-16 8,333 8,333 Direct
2024-05-22 8,333 8,333 Direct
2022-12-07 16,667 16,667 Indirect
Footnotes
  1. The reporting person acquired 21,053 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.